THERAPEUTIC ADVANCES IN INFECTIVE ENDOCARDITIS: NEW ANTIMICROBIALS, COMBINATION THERAPIES, AND CHALLENGES RELATED TO BIOFILM

Autores

  • José Antonio Pizzolato Neto
  • Rodolfo de Oliveira Medeiros
  • Cristiano Machado Galhardi
  • Paula Masi
  • Rafael Ignacio dos Santos
  • Sophia Evaristo Coércio
  • Luan Tavares Amadeu
  • João Felipi Fernandes Riguette
  • João Victor Laiola De Oliveira Barbosa
  • Letícia Cher Messias Pavoni
  • Manuela Mello Guerra
  • Pedro Henrique Lima Domingues

DOI:

https://doi.org/10.36557/2674-9432.2026v5n2p1541-1551

Palavras-chave:

Infective endocarditis; Antimicrobials; Biofilm; Combination therapy; Dalbavancin.

Resumo

Infective endocarditis remains a severe condition associated with high morbidity and mortality, prolonged hospitalizations, and the frequent need for a multidisciplinary approach. Despite the consolidation of classical antimicrobial regimens, recent years have brought new discussions on sequential therapies, long-acting antimicrobials, synergistic combinations, and strategies aimed at addressing biofilm, especially in infections caused by Staphylococcus aureus, coagulase-negative staphylococci, and enterococci. This study aimed to discuss therapeutic advances in infective endocarditis, with emphasis on new antimicrobials, combination therapies, and challenges related to biofilm. This is a narrative literature review based primarily on studies published between 2020 and 2026, retrieved from databases such as PubMed/MEDLINE, ScienceDirect, Springer, Scopus, and Web of Science. The findings indicate that drugs such as dalbavancin and oritavancin have been investigated as alternatives for therapeutic consolidation, particularly in selected and clinically stable patients. In addition, combinations such as daptomycin-ceftaroline have emerged as possibilities in persistent infections caused by resistant microorganisms. However, biofilm formation remains one of the main therapeutic obstacles, requiring integration between early diagnosis, appropriate antimicrobials, removal of infected devices, and eventual surgical intervention. It is concluded that therapeutic advances are promising, but still depend on robust evidence, clinical individualization, and integrated action by the endocarditis team.

Downloads

Não há dados estatísticos.

Referências

ALLAW, F. et al. ORAL THERAPY FOR INFECTIVE ENDOCARDITIS: WHERE DO WE STAND? Antibiotics, 2025. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12735454/. Accessed on: Apr 02, 2026.

APARICIO-MINGUIJÓN, E. et al. DALBAVANCIN AS SEQUENTIAL THERAPY IN INFECTIVE ENDOCARDITIS. Journal of Antimicrobial Chemotherapy, 2025. Available at: https://pubmed.ncbi.nlm.nih.gov/38902152/. Accessed on: Apr 02, 2026.

ASHRAF, H. et al. SAFETY AND EFFICACY OF OUTPATIENT PARENTERAL ANTIBIOTIC THERAPY IN INFECTIVE ENDOCARDITIS. Health Science Reports, 2025. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12076119/. Accessed on: Apr 03, 2026.

CHALDOUPIS, A. E. et al. DALBAVANCIN FOR INFECTIVE ENDOCARDITIS: A SYSTEMATIC REVIEW OF EFFECTIVENESS, SAFETY AND DOSING. European Journal of Clinical Microbiology & Infectious Diseases, 2026. Available at: https://link.springer.com/article/10.1007/s10096-026-05434-3. Accessed on: Apr 01, 2026.

DELGADO, V. et al. 2023 ESC GUIDELINES FOR THE MANAGEMENT OF ENDOCARDITIS. European Heart Journal, v. 44, n. 39, p. 3948-4042, 2023. Available at: https://doi.org/10.1093/eurheartj/ehad193. Accessed on: Apr 04, 2026.

GAVARUZZI, F. et al. LONG-TERM THERAPY WITH LONG-ACTING LIPOGLYCOPEPTIDE ANTIBIOTICS. Antibiotics, 2025. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12649424/. Accessed on: Apr 01, 2026.

GOODMAN-MEZA, D. et al. LONG-ACTING LIPOGLYCOPEPTIDES VS ANTIBIOTICS IN SERIOUS BACTERIAL INFECTIONS. JAMA Network Open, 2025. Available at: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2834350. Accessed on: Apr 01, 2026.

IMAZIO, M. et al. THE 2023 NEW EUROPEAN GUIDELINES ON INFECTIVE ENDOCARDITIS. European Heart Journal Supplements, 2024. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11365601/. Accessed on: Apr 01, 2026.

IVERSEN, K. et al. PARTIAL ORAL VERSUS INTRAVENOUS ANTIBIOTIC TREATMENT OF ENDOCARDITIS. The New England Journal of Medicine, v. 380, p. 415-424, 2019. Available at: https://pubmed.ncbi.nlm.nih.gov/30152252/. Accessed on: Apr 03, 2026.

KAUSHIK, A. et al. INFECTIVE ENDOCARDITIS BY BIOFILM-PRODUCING METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS: PATHOGENESIS, DIAGNOSIS AND MANAGEMENT. Journal of Clinical Medicine, 2024. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11672591/. Accessed on: Apr 04, 2026.

LEANZA, G. M. et al. A SYSTEMATIC REVIEW OF DALBAVANCIN EFFICACY AS A SEQUENTIAL THERAPY FOR INFECTIVE ENDOCARDITIS. Infection, 2025. Available at: https://pubmed.ncbi.nlm.nih.gov/39325353/. Accessed on: Apr 04, 2026.

LERCHE, C. J. et al. ANTI-BIOFILM APPROACH IN INFECTIVE ENDOCARDITIS EXPOSES NEW TREATMENT STRATEGIES FOR IMPROVED OUTCOME. Frontiers in Cell and Developmental Biology, 2021. Available at: https://doi.org/10.3389/fcell.2021.643335. Accessed on: Apr 02, 2026.

PEDERSEN, E. C. et al. BACTERIOPHAGE THERAPY AND INFECTIVE ENDOCARDITIS: IS IT REALISTIC? Clinical Microbiology and Infection, 2024. Available at: https://pubmed.ncbi.nlm.nih.gov/39007242/. Accessed on: Apr 01, 2026.

POLICARPO, S. et al. DAPTOMYCIN AND CEFTAROLINE COMBINATION THERAPY IN COMPLICATED ENDOVASCULAR INFECTIONS. Antibiotics, 2024. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10938187/. Accessed on: Apr 03, 2026.

PRIES-HEJE, M. M. et al. FIVE-YEAR OUTCOMES OF THE PARTIAL ORAL TREATMENT OF ENDOCARDITIS TRIAL. The New England Journal of Medicine, 2022. Available at: https://www.nejm.org/doi/full/10.1056/NEJMc2114046. Accessed on: Apr 03, 2026.

RAPTI, V. et al. THE EVOLVING LANDSCAPE OF INFECTIVE ENDOCARDITIS. Journal of Clinical Medicine, 2025. Available at: https://www.mdpi.com/2077-0383/14/6/2087. Accessed on: Apr 02, 2026.

SUÁREZ, M. et al. COMPARISON OF DALBAVANCIN WITH STANDARD OF CARE IN THE SEQUENTIAL TREATMENT OF INFECTIVE ENDOCARDITIS. International Journal of Antimicrobial Agents, 2024. Available at: https://pubmed.ncbi.nlm.nih.gov/37931892/. Accessed on: Apr 01, 2026.

Downloads

Publicado

2026-04-30

Como Citar

PIZZOLATO NETO, José Antonio et al. THERAPEUTIC ADVANCES IN INFECTIVE ENDOCARDITIS: NEW ANTIMICROBIALS, COMBINATION THERAPIES, AND CHALLENGES RELATED TO BIOFILM. Periódicos Brasil. Pesquisa Científica, Macapá, Brasil, v. 5, n. 2, p. 1541–1551, 2026. DOI: 10.36557/2674-9432.2026v5n2p1541-1551. Disponível em: https://periodicosbrasil.emnuvens.com.br/revista/article/view/939. Acesso em: 9 maio. 2026.

Edição

v. 5 n. 2 (2026): Periódicos Brasil. Pesquisa Científica - QUALIS A3

Seção

Ciências da Saúde

Licença

Copyright (c) 2026 José Antonio Pizzolato Neto, Rodolfo de Oliveira Medeiros, Cristiano Machado Galhardi, Paula Masi, Rafael Ignacio dos Santos, Sophia Evaristo Coércio, Luan Tavares Amadeu, João Felipi Fernandes Riguette, João Victor Laiola De Oliveira Barbosa, Letícia Cher Messias Pavoni, Manuela Mello Guerra, Pedro Henrique Lima Domingues

Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.

Você tem o direito de:

  1. Compartilhar — copiar e redistribuir o material em qualquer suporte ou formato para qualquer fim, mesmo que comercial.
  2. Adaptar — remixar, transformar, e criar a partir do material para qualquer fim, mesmo que comercial.
  3. O licenciante não pode revogar estes direitos desde que você respeite os termos da licença.  

 

De acordo com os termos seguintes:

  1. Atribuição — Você deve dar o crédito apropriado , prover um link para a licença e indicar se mudanças foram feitas . Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso.
  2. Sem restrições adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.